Skip to main content

Table 1 Results of mirincamycin in combination with DHA, CQ and TQ

From: Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates

  IC50(nM) IC90(nM) ΣFIC50a ΣFIC90a
Tafenoquine – mirincamycin (n) TQ MIR TQ MIR   
Field isolates (nb = 3) 2,962.85 2,357.12 9,027.36 15,653.18 0.56 0.50
3D7 (nc = 3) 1,348.48 19,539.36 2728.49 36,936.11 0.86 1.09
K1 (nc = 2) 1,076.23 24,736.61 5,271.96 39,284.24 0.88 1.03
All tested isolates (n = 8) 1,829.64 8,135.69 5,005.97 25,786.65 0.78 0.83
DHA – mirincamycin (n) DHA MIR DHA MIR   
Field isolates (nb = 4) 3.23 1,067.34 13.0 20,101.72 0.81 0.69
3D7 (nc = 3) 1.90 16,995.36 4.78 34,781.20 0.86 0.85
K1 (nc = 2) 1.09 8,669.49 2.86 27,749.81 0.71 0.95
All tested isolates (n = 9) 2.12 4,276.94 6.65 25,925.12 0.80 0.83
Chloroquine – mirincamycin (nb) CHL MIR CHL MIR   
Field isolates (nb = 2) 128.99 1,365.01 680.90 16,161.82 0.39 0.99
3D7 (nc = 4) 28.27 23,288.21 63.87 38,311.62 1,06 1.04
K1 (nc = 2) 651.93 18,869.50 1,174.69 36,535.66 0.95 0.99
All tested isolates (n = 8) 90.54 10,871.57 239.01 30,511.74 0.80 0.91
  1. aSynergy, <0.5; additivity, 0.5-2; antagonism,>2.
  2. bn, no. of fresh field isolates tested.
  3. cn, no. of repeats.
  4. Geometric mean IC50 and IC90 in nM for mirincamycin (MIR), tafenoquine (TQ), chloroquine (CHL) and dihydroartemisinin (DHA) as well as the sum of fractional inhibitory (ΣFIC) concentrations for P. falciparum field isolates and culture clones 3D7 (chloroquine-sensitive) and K1 (chloroquine-resistant) tested in checkerboards assays.